Brainstorm Cell Therapeutics (NSDQ:BCLI) said today it won a $16 million grant from the California Institute of Regenerative Medicine to engage in a phase 3 study of its NurOwn mesenchymal stem cell-based platform for treating amyotrophic lateral sclerosis.

Brainstorm said it is in the advanced stages of planning a Phase 3 clinical trial investigating NurOwn for treating ALS. The trial is slated to enroll approximately 200 patients at 6 sites in the US, with the primary outcome being an ALSFR-S score responder analysis.

Read the whole story on our sister site, Drug Delivery Business